Analysis Regulatory

CHMP backs Krka's generic of Jakavi across three indications; EC decision now pending

The 12 November positive opinion for Ruxolitinib Krka covers myelofibrosis, polycythaemia vera and graft-versus-host disease. What is settled, what is not, and what teams should check.

VigiEye editorial · Mon 16 Nov 2026

What happened

On 12 November 2026 the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Ruxolitinib Krka, a generic of Jakavi. The medicine is proposed for myelofibrosis, polycythaemia vera and graft-versus-host disease. The opinion now goes to the European Commission, which issues the legally binding marketing authorisation decision.

A CHMP opinion is a recommendation, not an authorisation. Until the Commission decides, Ruxolitinib Krka cannot be marketed in the EU under this authorisation. In general terms, the Commission normally adopts its decision within about two months of an opinion, though the records do not give a date for this one.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Sources this analysis is based on

Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.

More analysis & opinionAll →